The global Biotechnology market size reached USD 761.5 Billion in 2024 and is projected to grow to USD 1,315.9 Billion by 2033, exhibiting a CAGR of 6.27% during the forecast period of 2025-2033. Growth is driven by advancements in genetic engineering, increased R&D in personalized medicine, and the rising demand for sustainable agriculture.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
Biotechnology Market Key Takeaways
- Current Market Size: USD 761.5 Billion in 2024
- CAGR: 6.27% during 2025-2033
- Forecast Period: 2025-2033
- Biotechnology is a multidisciplinary science impacting healthcare, agriculture, and environmental management.
- Innovation in gene editing and personalized medicine drives market expansion.
- Healthcare is the largest application segment in the biotechnology market.
- North America holds the largest market share due to strong R&D, regulatory frameworks, and industry collaboration.
- Increasing use of bioinformatics and sustainable agriculture solutions foster market growth.
Sample Request Link:
https://www.imarcgroup.com/biotechnology-market/requestsample
Market Growth Factors
Innovation as the Primary Market Growth Catalyst
Advances in molecular biology and genetic research, including CRISPR-Cas9 gene editing, have fueled rapid innovation. The drive for personalized medicine and targeted treatments for chronic diseases has increased demand for biopharmaceuticals and precision medicine. Moreover, the need for sustainable agricultural solutions amid growing population pressures promotes biotechnology applications in crop improvement and biopesticides. The integration of bioinformatics optimizes data-driven R&D, while bioremediation and biofuels emphasize environmental sustainability, cumulatively accelerating biotechnology market growth.
Rapid Advancements in Genetic Engineering
The biotechnology market prominently benefits from breakthroughs in genetic engineering, notably CRISPR-Cas9, which enables precise gene modification. This supports the development of gene therapies for genetic disorders and cancers and boosts the production of valuable biochemical compounds like insulin and enzymes. Innovations in genetic engineering are transforming medical treatments, agriculture crop resistance, and industrial biotechnology processes, establishing this technology as a core market driver in precision therapeutics and sustainable biomanufacturing solutions.
Demand for Personalized Medicine and Sustainable Agriculture Solutions
Personalized medicine, using genomic sequencing to develop targeted therapies, is gaining momentum, enhancing treatment efficacy and reducing side effects. Biotechnology supports monoclonal antibodies and gene therapies aligned with personalized approaches. Concurrently, global food demand and environmental concerns increase adoption of GMOs, biopesticides, and climate-resilient crops, which reduce ecological impact and support food security. These biotechnology-driven advancements address urgent healthcare and agricultural challenges, underpinning sustained market growth.
Market Segmentation
Breakup by Product Type:
- Instruments: Foundation tools for advanced research and diagnostics, enabling precise experimentation.
- Reagents: Essential components that drive experimental processes for accurate results.
- Software and Services: Software supports data analysis and integration; services include consulting, training, and technical support that enhance biotechnology utilization.
Breakup by Technology:
- Nanobiotechnology: Combines nanoscale materials with biological systems to innovate drug delivery and therapies.
- Tissue Engineering and Regeneration: Develops functional tissues to address medical needs and organ shortages.
- DNA Sequencing: Enables genomic analysis critical for personalized medicine and disease understanding.
- Cell-Based Assays: Provides cellular insights for drug development and toxicity testing.
- Fermentation: Produces biofuels, pharmaceuticals, and enzymes, a key bioprocessing method.
- PCR Technology: Amplifies DNA to support diagnostics and genetic research.
- Chromatography: Separates biomolecules for purification and analytical processes.
- Others
Breakup by Application:
- Healthcare: Dominant segment using biotechnology for diagnostics, treatment development, and personalized medicine.
- Food and Agriculture: Includes genetically modified crops and biopesticides for enhanced yield and sustainability.
- Natural Resources and Environment
- Industrial Processing
- Bioinformatics
- Others
Breakup by Region:
- North America (United States, Canada)
- Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Regional Insights
North America currently dominates the global biotechnology market, driven by its strong ecosystem of research innovation and industry collaboration. This region benefits from substantial R&D investment, established regulatory frameworks, leading academic and biotech institutions, and venture capital emphasis that accelerates commercialization. North America’s influential role shapes the biotechnology landscape, fostering significant growth and transformative innovations.
Recent Developments & News
- In May 2025, Biogen and City Therapeutics formed a partnership to develop RNA interference (RNAi) therapies targeting central nervous system diseases, combining City Therapeutics’ platform with Biogen’s delivery technology.
- Also in May 2025, Biocon Biologics launched a biosimilar Ustekinumab BS Subcutaneous Injection [YD] in Japan through Yoshindo Inc., expanding its presence in the global biosimilar market.
- In April 2025, Novartis announced a USD 23 Billion investment over five years to expand US biotech and pharmaceutical operations, including new facilities and significant job creation.
- Amgen invested USD 900 Million in April 2025 to expand its Ohio biologics manufacturing site, increasing total investment to over USD 1.4 Billion and jobs to 750.
- In March 2025, Roche opened the Roche Genentech Innovation Center Boston, focusing on cardiovascular and metabolism R&D and AI-driven drug discovery, potentially employing up to 500 people.
Key Players
- Amgen Inc.
- Biocon Limited
- Biogen Inc.
- F. Hoffmann-La Roche AG
- Genmab A/S
- Lonza Group AG
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Seagen Inc.
- Syngenta AG
- Vertex Pharmaceuticals Incorporated
Ask For An Report Analyst:
https://www.imarcgroup.com/request?type=report&id=5785&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
